Corvus Pharmaceuticals, Inc. (CRVS) Reports In-Line Q2 EPS

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q2 EPS of ($0.18), in-line with the analyst estimate of ($0.18). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Adobe Systems (ADBE) Tops Q3 EPS by 6c, Offers Guidance
• Oracle raises full year profit guidance, stock rises after hours